As drug classes go, growth rates in anti-psychotics are actually quite healthy. But it's fairly well penetrated. It gets harder to grow as [the industry] gets bigger.
Can we think of this as a 10 or 11 percent top-line story again? That's unclear.
It looks like they kind of scraped by. Earnings were in line. Sales were a bit light, mostly on the drug side of the business. It's nothing to jump up and down about.
It wasn't a great quarter, but the expectations have gotten so low on J&J that a real ho-hum quarter is actually not a bad thing.
It's a classic situation of expectations getting ahead of the story.
It's more than fairly priced given the lack of visibility and a more constrained hospital (spending) environment.
Most people in cardiology would say that more is better. If Abbott does acquire the Guidant business, there's very little overlap. There's probably not a lot of restructuring to come.
That is always the elephant in the room with J&J. Everyone wants to know what is going on in M&A, and they're not saying.
They have been talking about streamlining operations and making their manufacturing more efficient. It's part of that story.
This website focuses on proverbs in the Swedish, Danish and Norwegian languages, and some parts including the links below have not been translated to English. They are mainly FAQs, various information and webpages for improving the collection.
This website focuses on proverbs in the Swedish, Danish and Norwegian languages, and some parts including the links below have not been translated to English. They are mainly FAQs, various information and webpages for improving the collection.